Intellia Therapeutics, Inc. $NTLA Stock Holdings Lowered by GSA Capital Partners LLP

GSA Capital Partners LLP lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 59.3% during the third quarter, Holdings Channel reports. The fund owned 75,091 shares of the company’s stock after selling 109,292 shares during the quarter. GSA Capital Partners LLP’s holdings in Intellia Therapeutics were worth $1,297,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NTLA. Vanguard Group Inc. grew its position in Intellia Therapeutics by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock worth $190,744,000 after purchasing an additional 192,651 shares during the last quarter. Geode Capital Management LLC grew its holdings in Intellia Therapeutics by 5.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company’s stock worth $24,449,000 after buying an additional 126,049 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Intellia Therapeutics by 73.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock worth $8,822,000 after buying an additional 396,858 shares in the last quarter. Armistice Capital LLC increased its position in Intellia Therapeutics by 78.6% in the 2nd quarter. Armistice Capital LLC now owns 650,000 shares of the company’s stock valued at $6,097,000 after acquiring an additional 286,000 shares during the period. Finally, Vestmark Advisory Solutions Inc. raised its stake in Intellia Therapeutics by 104.7% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 638,342 shares of the company’s stock valued at $5,988,000 after acquiring an additional 326,460 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the completion of the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the transaction, the chief executive officer directly owned 1,013,339 shares in the company, valued at approximately $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 53,051 shares of company stock valued at $488,600 over the last three months. Company insiders own 3.10% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $12.48 on Thursday. The firm’s 50 day moving average is $11.29 and its 200-day moving average is $12.93. Intellia Therapeutics, Inc. has a 12-month low of $5.90 and a 12-month high of $28.25. The stock has a market capitalization of $1.45 billion, a P/E ratio of -2.92 and a beta of 2.10.

Wall Street Analysts Forecast Growth

NTLA has been the subject of several recent analyst reports. Wedbush decreased their price target on Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Bank of America lowered their target price on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. Evercore set a $8.00 price target on shares of Intellia Therapeutics and gave the stock an “in-line” rating in a research report on Tuesday, November 11th. JonesTrading cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 11th. Finally, Guggenheim lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, October 27th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $17.48.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.